Qiming Venture Partners announced on Tuesday the final closing of its RMB-denominated Fund VI at 2.852 billion yuan ($440.3 million) as the China-based venture capital (VC) major ups its stake in early- and-growth-stage healthcare and TMT startups.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
